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3.83% prevalence. The 20 most frequent treatments accounts for 82.12 % (1016057) of 
total services. The following top-10 medical procedure were responsible for 58,05% 
(718.276) of total activities: 1) Ultrasound therapy 118806 (9.60%), 2) Iontophoresis 
100788 (8.15%), 3) Passive movement 80424 (6.50%), 4) Mid-frequency treatment 
77434 (6.26%), 5) Muscle strengthening exercises 62049 (5.02%), 6) Hand Massage 
62026 (5.01%), 7) Ergo therapy 60462 (4.89%), 8) Spinal Mobilization 57609 (4.66%), 
9) Diadynamic interference management 54092 (4.37%), 10) Training for circula-
tion improvement 44586 (3.60%). Physiotherapy out-patient care for Low Back Pain 
patients were 1.23 million cases with 294 million Hungarian Forint (0.96 million 
Euro) health insurance subsidy. ConClusions: The list of the 20 most frequent 
types of services reflects to the demand for the combination of active and passive 
exercises in Hungary. In case of capacity planning for diagnostic and therapeutic 
procedures, these findings should be considered.
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objeCtives: The number of hip fracture hospitalizations in the U. S. was approxi-
mately 352,000 in 2011 and expected to rise. The consequences of hip fractures are 
significant regarding the associated negative impacts on functioning and quality of 
life. Intertrochanteric hip fractures are frequently stabilized surgically using cepha-
lomedullary nails (CM). Complications may include post-operative femoral-shaft 
fracture, mechanical complications, and delayed/non-union, requiring reoperations 
that increase risk to the patient and cost to the health care system. Methods: A 
retrospective analysis of the Premier research database was conducted. Patients 
diagnosed with open and/or closed intertrochanteric fractures (ICD-9-CM codes 
820.2x or 820.3x) and treated for Hip Fracture (MS-DRG 480-482) from 1-JAN-2008 
through 30-JUN-2012 were included in the study. Among this population, patients 
treated with IM were identified using standard charge descriptions within orthope-
dic-implant hardware charges. To identify patients who had a reoperation, patient-
level admission records starting from index admission up to 12-months post-index 
procedure were investigated within the same MS-DRG classifications. Results: 
Overall, 73,745 patients qualified for the study (71% female; 74% ≥ 75-years-old). 
Of these, 32,175 (44%) were treated using CM. The average hospital cost of the 
index procedure was $15,798USD per patient (inclusive of fixed and variable costs), 
of which the average cost of the orthopedic nails was $1,704USD. Among these 
patients, a total of 419 (1.3%) patients were readmitted at 427 occasions within the 
12-month study period. The mean hospital cost of treating these readmissions was 
$16,352USD, and the primary diagnoses codes for these readmissions included fem-
oral fractures, nonunions, and device/mechanical complications. ConClusions: 
Although the incidence of readmission following a hip fracture is low, the eco-
nomic burden placed on the health care system and the humanistic burden are 
both significant. The incidence rate and long-term sequelae for hip fractures are 
well documented in the literature; however, the mean costs to a hospital have not 
yet been published.
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objeCtives: The Hungarian health budget does not allow all candidates to be 
promptly operated on with vertebral malformation. The budget is enough for 
approximately 4000 stabilizations by implant. The rest have to be put on the wait-
ing list. The aim of our study is to analyse the costs related to the patients being on 
waiting list for surgery of vertebral malformation. Methods: Data derived from 
the nationwide financial database of the Hungarian National Health Insurance Fund 
Administration. 71 patients on waiting list of an institute in 2005-2006 were studied. 
We analysed the average waiting time and the costs related to patients either oper-
ated on or without operation. Results: The average age of all candidates was 55 
year and the average waiting time was 32 months. The treatment cost during the 
waiting time was US$ 103 per month per patient. The average age of candidates 
operated on was 57 years and their average waiting time was 15 months with a costs 
of US$ 155 per month per patients. The average age of candidates not operated on 
was 54 years and their average waiting time was 15 months with a cost of US$ 92 
per month per patient. ConClusions: Half of candidates have not been operated 
on, because at the appointed date they postponed the operation. But they seem not 
to really want to be operated on. The reason could be they were not sure enough to 
be able to get job after the operation at their age.
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objeCtives: Target measures such as DAS-28 < 2.6 are the goal of treatment in 
rheumatoid arthritis (RA). In general, DAS-28< 2.6 is associated with improved func-
tionality and reduced resource use but with higher treatment costs. This study 
evaluated whether treatment strategies that were more effective but more expen-
sive in achieving DAS-28< 2.6 in moderate to severe RA patients were cost effective 
(CE). Methods: A micro-simulation model of 10,000 RA patients was developed 
that estimated lifetime Health Assessment Questionnaire (HAQ) progression, quality 
adjusted life years (QALYs) and direct costs from a UK NHS perspective. The model 
incorporated an initial response criterion of achieving a DAS-28 < 2.6 at 6 months 
lost. ConClusions: The most important indirect costs in Italy from 2009 to 2012 
was represented by disability benefits (69% of the total indirect cost), followed by 
disability pensions (28% of cost) and incapacity pensions (3% of cost). A better pre-
scription appropriateness and rapid access to innovative treatments (Italy, among 
the EU Countries, is the one with the greatest delay in access) would reduce the 
costs incurred by the social security system accompanied by an improvement on 
the effectiveness of interventions.
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objeCtives: Societal cost evidence relating to patients with psoriatic arthritis (PsA) 
is required to understand the overall economic impact of the disease. The objective 
of this research was to systematically review the published data relating to the soci-
etal burden of PsA. Methods: Embase, Medline, and Cochrane databases (accessed 
November 2013) were interrogated. Studies reporting on non-health sector costs or 
work disability associated with PsA were eligible for inclusion with no geographical 
restriction. Results: In total, 19 studies met eligibility criteria of the review; nine 
studies reported indirect costs associated with PsA and 11 studies reported PsA-
related work disability. Studies were conducted across Europe, USA, Canada, and 
Asia. Methodology used to calculate indirect cost estimates differed among studies; 
seven studies defined indirect costs as costs associated with productivity loss only, 
and two studies adopted a wider definition whereby indirect costs included produc-
tivity loss and out-of-pocket costs expenses (e. g. transportation, informal care, and 
home aids). Annual indirect cost associated with PsA, calculated using the human 
capital or friction capital approach, ranged from € 1,261 (Spain) to € 7,919 (Germany), 
with the majority of studies (71%) reporting annual indirect costs of less than € 4,000 
per person. Considerable heterogeneity was reported, with indirect costs of € 74,009 
over a two year period estimated in Norway, compared with 6-month costs of € 576 
in Italy. Indirect costs accounted for between 38% and 72% of total costs. Work 
disability estimates ranged from 5% to 39%. Disease severity, age, and gender were 
reported as main drivers of indirect costs and work disability. ConClusions: Cost 
associated with productivity loss represented the majority of indirect costs associ-
ated with PsA. Comparison of studies is confounded by heterogeneity between 
studies. Further research into the societal costs associated with patients with PsA 
in the UK is required as no studies reporting UK specific costs were identified.
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objeCtives: Ankylosing spondylitis (AS), one of the most common spondyloarth-
ritides, is a chronic condition with a significant impact on patient quality of life 
(QoL), particularly physical functioning. The objective of this research was to sys-
tematically review published data relating to the societal burden of AS. Methods: 
Embase, Medline, and Cochrane databases (accessed November 2013) were interro-
gated. Studies reporting on non-health sector costs or work disability associated with 
AS were eligible for inclusion. Results: In total, 42 studies met eligibility criteria; 19 
studies reported indirect costs associated with AS and 23 studies reported AS-related 
work disability. Studies were conducted across Europe, Africa, North America, and 
Asia. All studies defined indirect costs as costs associated with productivity loss. 
Annual indirect costs, calculated using the human capital approach, ranged from € 595 
(Belgium) to € 9,837 (Germany). Friction costs calculated ranged from € 428 (France) to 
€ 6,843 (Spain). Considerable heterogeneity was reported, with 2-year indirect costs 
of € 66,907 estimated in Norway. Despite heterogeneity between studies, 75% of pub-
lications reported indirect costs of less than € 4,500 per patient/year, representing 
between 34% and 74% of total costs. Non-medical costs such as informal care, and 
transportation ranged from $65 (US) to $3,663 (US), indicating that loss of productivity 
was the main driver of indirect costs. Estimates of work disability varied greatly across 
studies primarily due to heterogeneous populations and the lack of standardised 
questionnaires. The work disability of AS was multifactorial with regression analyses 
identifying several factors associated with both indirect costs and disability includ-
ing demographic factors, disease and job characteristics. ConClusions: Although 
reported indirect costs and work disability estimates varied between studies, findings 
from this systematic review indicate that AS represents a substantial burden both on 
society and individuals with AS. A lack of UK-based data illustrates the challenge of 
incorporating societal costs into future UK reimbursement submissions.
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objeCtives: The aim of our study is to assess amount and frequency of the physi-
otherapy services in Low Back Pain disease and determine the total health insurance 
reimbursement. Methods: Data were derived from the countrywide database of 
Hungarian Health Insurance Administration (HHIA), based on official reports of 
outpatient care institutes in 2009. The total numbers of different physiotherapy 
services were determined by selecting the reported specific diagnoses codes and 
counting the number treatments provided for that specific diagnosis code. The dif-
ferent types of treatment codes are listed in the chapter of the Guidelines of HHIA 
for `Physiotherapists, massage-therapists, conductors and other physiotherapy 
practices`. The Low Back Pain was reported according to WHO ICD diagnosis code 
M5450. Results: Low Back Pain account for 1237263 cases in the annual number 
of the physiotherapy-related activities (32318413 cases) showing an approximately 
